Samsung BioLogics, Below the estimate of operating profit for the 3rd quarter(Yuanta Securities)
Samsung BioLogics, Below the estimate of operating profit for the 3rd quarter(Yuanta Securities)
  • 안호현 전문기자
  • 승인 2020.10.22 12:03
  • 최종수정 2020.10.22 11:49
  • 댓글 0
이 기사를 공유합니다

삼성바이오로직스 CI
Samsung BioLogics CI

[Infostock Daily= Reporter An Hoe Hyun] Yuanta Securities maintained its investment opinion 'Buy' and target stock price of 1.08 million won on the 22nd, saying Samsung BioLogics’ third-quarter operating profit fell short of the market consensus, but its operating profit ratio remained solid.

Samsung BioLogics recorded sales of 274.6 billion won and operating profit of 56.5 billion won in the third quarter. The figure rose 48.6% and 139.3%, respectively, from a year earlier. However, sales exceeded 12.1% compared to the consensus(245 billion won), but operating profit was 12.2% lower than the consensus(64.4 billion won).

"Operating profit fell 30.3% from the previous quarter(second quarter) due to increased costs and payment fees for manpower recruitment," the company explained, adding, "Nevertheless, the operating profit ratio remained at a solid level at 20.6%."

Yuanta Securities predicted that it will stabilize as the plant maintenance cycle, one of the factors that caused the company's performance volatility, is prolonged.

"The factory operation rate in the third quarter, which will be reflected in sales in the fourth quarter, is 70% of the first plant, 100% of the second plant and mid 20% of the third plant. The performance is stabilizing," the company explained, adding, "The operation rate of the first and second plants has stabilized, and the operation rate of the third plants is expected to reach up to 30% annually."

Yuanta Securities forecast Samsung BioLogics' sales of 996.7 billion won and operating profit of 233.3 billion won this year.

Reporter An Hoe Hyun ahh@infostock.co.kr


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.